Photocure fundamentale forhold (PHO)

Fornybar · januar 2, 2022, 7:44am

Ny og ny? Registrerte seg januar 2020 og har 28 følgere. What is this

Andre10k · januar 3, 2022, 6:52am

PHO: STARTER KOMMERSIELT SALG AV CYSVIEW I CANADA

Oslo (Infront TDN Direkt): Photocure vil i dag starte salg, markedsføring og distribusjon av Cysview i Canada.

Det fremgår av en melding mandag.

–Vi er veldig glade for å integrere det kanadiske markedet inn i vårt amerikanske segment, hvilket vil utvide den direkte markedsmuligheten for Cysview med omtrent 10 prosent, sier Daniel Schneider administrerende direktør i selskapet.

Mari Nøvik [email protected]

Infront TDN Direkt, +47 21 95 60 71

ufo · januar 12, 2022, 5:27pm

https://journey.ct.events/view/6e58de92-4aeb-44d6-bb5c-f815d8e7928f

H.C. Wainwright BioConnect 2022 Virtual Conference

Veldig bra gjennomgang av dan schneider.

$$$$$$---- Snadder fra Schneider----$$$$$$

Det flere 10-årene gamle utstyret blir avløst av siste generasjons scope fra den tyske produsenten og kommer på markedet våren 22.

TekBot · januar 20, 2022, 7:57am

Major shareholder disclosure - Photocure ASA

Bonus · januar 22, 2022, 7:59pm

Intressang analyse som kom ut 24/12-2021 som også tar for seg historien til Photocure.
Den er på Svensk, og lesevendlig

Kan ikke se de har fått med noe kursmål, men en bra gjennomgang av selskapet.

Tekspert · februar 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Rodjer (96 likes)

@Savepig (80 likes)

@myk (76 likes)

[quote=“myk, post:5300, topic:18877”]

Resten av topp 10:

@rosk82 (68 likes)
@OYV (46 likes)
@gabster (39 likes)
@CanonBoy (39 likes)
@Quadruple (34 likes)
@Snoeffelen (28 likes)
@HO5 (21 likes)

Gratulerer!

TekBot · februar 4, 2022, 7:12am

Photocure ASA – Major shareholding disclosure

TekBot · februar 7, 2022, 6:25am

Bladder Cancer technology: New improved Blue Light Cystoscopy system receives FDA approval for use in NMIBC in the U.S.

Oslo, Norway, February 7, 2022: Photocure ASA, The Bladder Cancer Company,
announces U.S. Food and Drug Administration (FDA) approval of a new and improved
Blue Light system to be used with Photocure’s Cysview[®] product in Blue Light
…

Vis børsmeldingen

Cystoscopy (BLC[®]) procedures for the detection of NMIBC*. Manufactured and
soon to be commercialized by KARL STORZ Endoscopy-America, Inc. (KARL STORZ),
the new Blue Light system is approved for use in procedures requiring rigid
cystoscopy. FDA approval was granted to KARL STORZ on February 4, 2022.

“The successful FDA approval is great news for the bladder cancer community in
the U.S.,” commented Geoffrey Coy, Vice President and General Manager, North
America at Photocure. “In healthcare, constant technical innovation is crucial,
and we expect that this new, enhanced BLC system will fulfill our clients’
expectations for improving the Blue Light experience. The new system is the next
generation and includes practical features to make the technology more user
friendly. We look forward to expanding the use of BLC with Cysview[®],” Geoffrey
Coy concluded.

“At KARL STORZ, we are committed to helping our customers deliver top-quality
care, and we believe that our new Blue Light system demonstrates this
commitment,” said Michael Lyman, Executive Director, Sales & Marketing, Urology
and Gynecology, KARL STORZ Endoscopy-America. “The New Blue Light Powered by
Saphira[®] will allow us to serve the needs of our customers, providing next
-level visualization to enable the right solutions for urological procedures in
patients with Non-Muscle Invasive Bladder Cancer and continue our collaboration
with the Photocure team to make high-quality BLC available to more patients in
the U.S.”.

Photocure expects to inform its stakeholders about the launch of the new Blue
Light system as KARL STORZ provides further information regarding the product
and its launch plans.

*NMIBC: non-muscle invasive bladder cancer

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA and KARL STORZ Endoscopy. Hexvix[®]/Cysview[®] and
BLC[®] are registered trademarks of Photocure ASA. Saphira[®] is a registered
trademark of KARL STORZ Endoscopy.

This press release may contain product details and information which are not
valid, or a product that is not accessible, in your country. Please be aware
that Photocure does not take any responsibility for accessing such information,
which may not comply with any legal process, regulation, registration, or usage
in the country of your origin.

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide, with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to
Our Partners for further information on our
commercial partners.

About Photocure ASA

Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

About KARL STORZ Endoscopy-America, Inc.

KARL STORZ Endoscopy-America, Inc., is an affiliate of KARL STORZ SE & Co. KG,
an international leader for more than 75 years in advanced medical technology,
providing surgical and procedural imaging, instrumentation, and enterprise-wide
integration. Based in Tuttlingen, Germany, KARL STORZ SE & Co. KG is a family
-owned company that designs, engineers, manufactures, and markets all its
products with an emphasis on visionary design, precision craftsmanship, and
clinical effectiveness. For more information, call (800) 421-0837 or visit the
company’s website at www.karlstorz.com.

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: [email protected]

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: [email protected]

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]

Kilde

TekBot · februar 8, 2022, 2:08pm

Major shareholder disclosure in Photocure ASA

Bonus · februar 8, 2022, 2:21pm

TekBot · februar 11, 2022, 9:06am

Photocure Partner Asieris announces Approval to conduct a Phase III Clinical Trial for Hexvix in China

Oslo, Norway, February 11, 2022: Photocure ASA (PHO: OSE), The Bladder Cancer
Company, announces that its partner Asieris Pharmaceuticals (SSE: 688176) has
obtained the Phase III clinical trial application (CTA) approval from the
…

Vis børsmeldingen

National Medical Products Administration (NMPA) of China for Hexvix[®].

The study is a prospective, multicenter bridging trial aimed to investigate the
additional detection rate and safety of Hexvix[®] and blue light cystoscopy
(BLC[®]) versus white light cystoscopy in Chinese patients with non-muscle
invasive bladder cancer (NMIBC, tumor types CIS, Ta, T1). The study will be led
by Peking Union Medical College Hospital, Chinese Academy of Medical Sciences.
Professor Li Hanzhong, head of the Department of Surgery, Peking Union Medical
College Hospital, will serve as the Principal Investigator to lead a team of top
experts in the field of bladder cancer in China to carry out this study.

According to Frost & Sullivan, the number of new bladder cancer cases in China
reached 86,000 in 2020, and is expected to rise to 101,000 in 2025, with a
compound annual growth rate of 3.4% during the period. The total number of
patients with bladder cancer in China was estimated to be higher than 600,000 in
2020. The use of BLC with Hexvix for the management of NMIBC is included in the
global expert consensus guidelines.

In January 2021, Asieris Pharmaceuticals entered into a license agreement with
Photocure, obtaining exclusive rights to register and commercialize Hexvix in
mainland China and Taiwan. In December 2021, Hexvix was put into pilot use in
the Boao Lecheng International Medical Tourism Pilot Zone in Hainan Province:
the first patient in China received blue light cystoscopy with Hexvix at Hainan
General Hospital (404: Not found
-patient-procedure-with-hexvix-in-china-under-special-access-program-4149992).

“We are very glad that the phase ? trial of Hexvix has been approved by the
NMPA” said Dr. Yong Xue, Chief Medical Officer of Asieris. “We will accelerate
the clinical trial process so that doctors and patients in China will have
access to this breakthrough technology as early as possible.”

“This clinical registration trial is a critical step toward giving bladder
cancer patients access to Hexvix in China. Hexvix is a diagnostic agent that has
been proven to improve the detection, and completeness of resection of tumors,
and can be an important solution in the management of disease”, said Anders
Neijber, Vice President Global Medical Affairs and Clinical Development at
Photocure.

Read Asieris’ full media release here: https://asieris.com/asieris-announced
-hexvix-a-drug-for-diagnosis-of-bladder-cancer%ef%bf%bc-has-obtained-the-ind
-approval-from-the-nmpa-for-phase-%e2%85%b2-clinical-trial/

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia and New Zealand. Please refer to
Our Partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: [email protected]

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: [email protected]

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]

Kilde

TekBot · februar 17, 2022, 9:07am

Photocure ASA: Invitation to presentation of 4th quarter and preliminary full year 2021 financial results

Oslo, Norway, 16 February 2022: Photocure ASA (Photocure, PHO: OSE) will
announce the fourth quarter and preliminary full year 2021 financial results on
Wednesday 23 February 2022 at 07:30 CET and invites investors, analysts and the
…

Vis børsmeldingen

media to a presentation at 14:00 CET the same day.

The investor presentation will be streamed live and be hosted by Daniel
Schneider, CEO and Erik Dahl, CFO. The presentation will be held in English and
questions can be submitted throughout the event.

The quarterly report and presentation will be published at 07:30 CET and will be
publicly available at www.photocure.com. The streaming event is available
through https://channel.royalcast.com/landingpage/hegnarmedia/20220223_10/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:

Photocure
Erik Dahl
CFO
Tel: +47 45055000
Email: [email protected]

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway) Tel: +47 91540000
Email: [email protected]

About Photocure
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

This information is subject to the disclosure requirements pursuant to section 5
-12 of the Norwegian Securities Trading Act.

Kilde

TekBot · februar 23, 2022, 6:32am

Photocure ASA: Results for the fourth quarter of 2021

Oslo, Norway, 23 February 2022: Photocure ASA (OSE:PHO) today reported
Hexvix[®]/Cysview[®] revenues of NOK 94.2 million in the fourth quarter of 2021
(Q4 2020: NOK 97.7 million). Unit sales in the U.S. and Europe rose 11% and 12%,
…

Vis børsmeldingen

respectively, while the revenue comparison was impacted by a one-time reversal
of an accrual in the prior-year period and foreign exchange. Photocure has a
solid pipeline of anticipated Blue Light Cystoscopy (BLC) tower installations in
the U.S. and expects placements to accelerate during the second half of 2022.

“Photocure showed strong execution and resilience in 2021 as we continued to
grow our U.S. business and successfully completed our first full year of
operations in continental Europe despite several surges of Covid-19. While
product revenue declined 4% in the fourth quarter of 2021 due to a one-time
accrual reversal in Q4 2020 and the impact of foreign exchange, fourth quarter
unit sales in the U.S. and Europe rose 11% and 12%, respectively year-over-year.
We are particularly pleased with the progress that we made during the 2-year
pandemic period, given the challenging conditions. Procedure volumes for bladder
cancer resection surgeries in the U.S. declined 11%, while we grew Cysview unit
volume by 24% from 2019 to 2021, resulting in an increase in our market
penetration,” says Daniel Schneider, President & Chief Executive Officer of
Photocure.

Photocure reported total group revenues of NOK 94.5 million in the fourth
quarter of 2021 (NOK 97.9 million), and an EBITDA* of NOK -5.5 million (NOK 15.2
million). Adjusted for the one-time reversal of an accrual in the fourth quarter
of 2020, Hexvix/Cysview revenues increased 5% in the fourth quarter 2021 and
were up 10% in constant currencies. The EBIT ended at NOK -11.5 million (-6.2)
and the cash balance at the end of the fourth quarter 2021 was NOK 322.9
million. The installed base of rigid cystoscopes in the U.S. was 311 at the end
of the fourth quarter, an increase of 43 units or 16% since the same period in
2020, including a total base of 48 flexible cystoscopes.

“Demand for BLC equipment remains very strong, and while some customers are
awaiting the launch of the new Karl Storz system, we placed 9 towers in the
fourth quarter. Our backlog for new capital equipment continues to grow, and we
are extremely pleased that Karl Storz’s new blue light system was approved by
the FDA earlier this month. As a result, both Photocure and Karl Storz are
energized and preparing to launch this new system in the coming months,”
Schneider adds.

The Company’s pipeline of anticipated BLC tower installations in the U.S.
remains robust given the demand by physicians and facilities to offer the
benefits of BLC with Cysview in their practices. With the new Karl Storz blue
light system anticipated to launch throughout the U.S. in the second quarter of
2022, Photocure expects that the placements of new blue light rigid towers will
accelerate in the back half of the year. Meanwhile, the Company will continue to
focus on increasing the use of Cysview in existing accounts as well as placing
flexible BLC equipment, for which installation momentum is increasing.

“While the worldwide pandemic required us to take measures to manage through a
period of great uncertainty, we used that time and deployed the necessary
resources to position our global commercial organization to drive significant
Hexvix/Cysview growth once healthcare access returns to normal. With our
European operations fully integrated, a new high-definition BLC system launching
in the U.S. market, and Covid-19 becoming better managed, we believe that 2022
will be an exciting year for Photocure as we help more bladder cancer patients
realize the benefits of Hexvix/Cysview,” Schneider concludes.

Please find the full financial
report (https://cms.photocure.com/uploads/PHO_Q4_2021_REP_39502dc94a.pdf) and
presentation (https://cms.photocure.com/uploads/Photocure_Q4_2021_Earnings_Slide_
Deck_Final_02_22_22_v2_ece5873a57.pdf) enclosed.

EBITDA* and other alternative performance measures (APMs) are defined and
reconciled to the IFRS financial statements as a part of the APM section of the
fourth quarter 2021 financial report on page 24.

Photocure will present its fourth quarter 2021 report on Wednesday 23 February
2022 at 14:00 CET. The investor presentation will be streamed live and be hosted
by Daniel Schneider, CEO and Erik Dahl, CFO.

The presentation will be held in English and questions can be submitted
throughout the event. The streaming event is available through
https://channel.royalcast.com/landingpage/hegnarmedia/20220223_10/

The presentation is scheduled to conclude at 14:45 CET.

For further information, please contact:
Dan Schneider
President and CEO
Photocure ASA
Tel: + 1-609 759-6515
Email: [email protected]

Erik Dahl
Chief Financial Officer
Tel: +47 450 55 000
Email: [email protected]

David Moskowitz
Vice President of Investor Relations
Tel: +1 202 280 0888
Email: [email protected]

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This information is considered to be inside information pursuant to the EU
Market Abuse Regulation and is subject to the disclosure requirements pursuant
to section 5-12 of the Norwegian Securities Trading Act. This stock exchange
announcement was published by Tolv Hillestad, Group Controller, Photocure ASA,
on 23 February 2022 at 07:30 CET.

Kilde

TekBot · februar 28, 2022, 6:32am

Photocure Announces the Publication of Pre-Clinical Study Results Supporting the Anti-tumor Effect of Hexaminolevulinate with Blue Light in Bladder Cancer model

Press release - Oslo, Norway, 28 February 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces the publication of new results from its
exploratory research program in the journal Biomedicines, entitled "Antitumor
…

Vis børsmeldingen

Effect and Induced Immune Response Following Exposure of Hexaminolevulinate
(HAL) and Blue Light in an Orthotopic Model of Rat Bladder Cancer". These
results support initial pre-clinical data on the potential anti-tumor effect of
HAL, which were presented at the BLADDR 2019 congress
[404: Not found
-the-bladdr-2019-congress-3457632].

The study objective was based on the hypothesis that the positive impact on long
-term outcomes in NMIBC patients who had undergone Blue Light Cystoscopy (BLC)
prior to cystectomy could be caused by a direct anti-tumor effect and/or
activation of the immune system indicating an additional effect of Blue Light
with HAL beyond pure detection. Therefore, as an exploratory preclinical study,
the authors investigated whether intravesical administration of HAL followed by
a diagnostic blue-light illumination-regime, aiming to mimic the one used
currently in Photodynamic Diagnosis (PDD), could have anti-tumor and/or immune
modulating effects as seen with Photodynamic therapy (PDT). In addition, it was
explored if co-administration of a checkpoint inhibitor would increase the
susceptibility to the PD-1/PD-L1 pathway inhibition thus increasing the anti
-tumor effect. Over the years, Photocure has conducted a number of experiments
on “mechanisms of actions” effects of HAL, as well as to see if there
potentially are similar anti-tumor and immune modulating effects of PDD with
blue light as reported with PDT. For this study, rats were treated with HAL and
blue light in an orthotopic model of bladder cancer, and then subjected to
histopathological analysis of the bladder samples and additional assessment of
immune markers. Co-administration of HAL and blue light with a checkpoint
inhibitor was further evaluated in this model aiming to assess for potentiation
of anti-tumor effects when combined with an immunotherapy.

Results of the study demonstrated an anti-tumor effect of HAL and blue light
when aiming to mimic the dosing regimen of a photodynamic diagnostic procedure
(PDD) in an orthotopic bladder cancer model in rats.

The authors conclude “The anti-tumor effect is most probably pertaining to
stimulation of the immune system as evident by tumor infiltration of CD3+ and
CD8+ T-cells. These results support our hypothesis that the positive impact on
patient outcomes observed in patients who had undergone BLC prior to cystectomy
could be explained by systemic immune activation induced by HAL and blue light.
Combination of HAL and blue light with intravesical anti-PD-L1 resulted in
increased anti-tumor effects. Further studies are warranted to explore the long
-term effects of HAL and blue light alone or in combination with checkpoint
inhibitors which should extend to investigate any systemic (abscopal) effects.
Intriguingly is also the idea that local treatment with HAL and blue light can
prime an immune response with potential additional effect of checkpoint
inhibitors.”

“The intriguing results from this pre-clinical study are encouraging and might
explain an effect of HAL+BL beyond pure detection. The results motivate further
research to evaluate the potential of HAL as a photodynamic therapy (PDT), which
may be an innovative technique for treatment of non-muscle invasive bladder
cancer.”, said Anders Neijber, Vice President, Global Medical Affairs and
Clinical Development at Photocure.

Read the full article here: Biomedicines | Free Full-Text | Antitumor Effect and Induced Immune Response Following Exposure of Hexaminolevulinate and Blue Light in Combination with Checkpoint Inhibitor in an Orthotopic Model of Rat Bladder Cancer

Note to editors

All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide, with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate, with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all cases and include
the subtypes Ta, carcinoma in situ (CIS), and T1 lesions. In MIBC, the cancer
has grown into deeper layers of the bladder wall. These cancers, including
subtypes T2, T3, and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [January 2022].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657
[3] Sievert KD et al. World J Urol 2009;27:295-300
[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)

Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder, making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview, compared to standard white light cystoscopy alone, improves
the detection of tumors and leads to more complete resection, fewer residual
tumors, and better management decisions.

Cysview[ ]is the tradename in the U.S. and Canada, Hexvix[ ]is the tradename in
all other markets. Photocure is commercializing Cysview/Hexvix directly in the
U.S. and Europe and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Chile, Australia, and New Zealand. Please refer to
Our Partners for further information on our
commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway, and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]

Erik Dahl
CFO
Photocure ASA
Tel: +4745055000
Email: [email protected]

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: [email protected]

Media and IR enquiries:

Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]

Kilde

Bonus · februar 28, 2022, 7:07am

Dette må jo være en meget hyggelig melding, det å kunne bevise att HAL har Anti-tumor effekt.

Dette har vel vært spekulert i tidligere, men nå ser det ut som det er bevist.

Dette vil utgjøre en enorm fordel for Photocure sin blærekreft satsing å kunne bevise att Hexvix har en Immune Response.

Oddbear · februar 28, 2022, 7:12am

Jeg ville vært litt forsiktig med å bruke utrykket “bevis”, men dette bør medføre at enhver blærekreftpasienter ønsker å la seg behandle med Cys/Hex.

Bonus · februar 28, 2022, 7:20am

Retter det til “probbaly”

Men én fantastisk nyhet er det jo.

The authors conclude “The anti-tumor effect is most probably pertaining to
stimulation of the immune system as evident by tumor infiltration of CD3+ and
CD8+ T-cells. These results support our hypothesis that the positive impact on
patient outcomes observed in patients who had undergone BLC prior to cystectomy
could be explained by systemic immune activation induced by HAL and blue light.
Combination of HAL and blue light with intravesical anti-PD-L1 resulted in
increased anti-tumor effects. Further studies are warranted to explore the long
-term effects of HAL and blue light alone or in combination with checkpoint
inhibitors which should extend to investigate any systemic (abscopal) effects.
Intriguingly is also the idea that local treatment with HAL and blue light can
prime an immune response with potential additional effect of checkpoint
inhibitors.”

Syvcys · februar 28, 2022, 7:52am

Jeg har selv sett dette forklart av en forskerkollega på en skjerm for ca 3 år siden, vedkommende prøvde å få til et samarbeid med pho uten å lykkes. Her var det tydelig at celler som hadde tatt opp cysview som ble bestrålt med blått lys døde fordi et livsnødvendig molekyl ble spaltet.

Tekspert · mars 1, 2022, 10:00am

Hver måned kårer jeg det jeg kaller Teksperter™ for noen av de mest populære investeringene våre

Det er de 3 medlemmene som har fått flest likes på innleggene sine de siste 90 dagene. Teksperter™ får også en unikt merke på profilen sin og et trofé-ikon ved siden av navnet sitt. Du kan bli Tekspert™ i flere aksjer/investeringer, og troféet vil bare vises i tråder der du er Tekspert™.

Her er denne månedens Teksperter™ og det mest likte innlegget deres fra de siste 90 dagene:

@Savepig (109 likes)

@Rodjer (89 likes)

@gabster (74 likes)

Resten av topp 10:

@myk (64 likes)
@rosk82 (43 likes)
@CanonBoy (37 likes)
@OYV (33 likes)
@Quadruple (30 likes)
@Snoeffelen (24 likes)
@TyrionIV (23 likes)

Gratulerer!

TekBot · mars 4, 2022, 7:02am

Photocure announces Endotherapeutics Group as New Commercial Partner for Hexvix in Australia & New Zealand

Press release - Oslo, Norway, 4 March 2022: Photocure ASA (OSE: PHO), the
Bladder Cancer Company, announces that it has entered into an exclusive
distribution agreement with Endotherapeutics Group for the commercialization of
…

Vis børsmeldingen

Hexvix[®] in Australia and New Zealand, and has terminated its distribution
agreement with Juno Pharmaceuticals (Juno). Under the new agreement,
Endotherapeutics will hold Marketing Authorizations and will re-launch Hexvix in
the two territories. All three parties will work closely together to ensure a
streamlined transfer and uninterrupted Hexvix supply to customers.

Endotherapeutics is a leading diversified medical technologies company focused
on improving healthcare in Australia and New Zealand for over 20 years across
several specialty areas. Its subsidiaries in Australia (Endotherapeutics Pty.
Ltd) and New Zealand (Endotherapeutics NZ Ltd, trading as Endoventure) will be
responsible for the commercialization of Hexvix in their respective territories.

Urology and men’s health represent important treatment segments for
Endotherapeutics, with a highly qualified and experienced urology team that is
customer focused and provides access to technologies and clinical support to the
private and public health care sectors. Endotherapeutics Pty. Ltd and
Endoventure are the exclusive distributors of the HIVECT bladder recirculation
system in Australia and New Zealand used in the treatment of bladder cancer*.
Endotherapeutics’ already established relationships with Urologists treating
bladder cancer offers clear synergies for the simultaneous promotion of Hexvix.

Photocure and Juno have mutually agreed to terminate their distribution
agreement dating back to 2015. Since in-licensing Hexvix, Juno’s business model
has evolved towards a focus on off-patent hospital tender products and away from
the regular sales, service and support required to market Hexvix. Photocure and
Juno will support Endotherapeutics to ensure a smooth transition and
uninterrupted supply of the product.

“We are pleased to enter into this agreement with Endotherapeutics to distribute
and market Hexvix in Australia and New Zealand. Their regional presence,
expertise and relationship with urologists is impressive. We are looking
forward to working with them to bring the benefits of BLC with Hexvix to
patients who suffer from bladder cancer,” said Dan Schneider, President and CEO
of Photocure.

“We look forward to adding Hexvix to our suite of products in urology care and
bringing it to more clinics and hospitals in Australia and New Zealand to
improve the quality of bladder cancer management. Our preliminary discussions
with top clinicians who treat bladder cancer confirm that there is a significant
need for Hexvix. It is a privilege to work with the Photocure team and the blue
light cystoscopy equipment providers to broaden the use of Hexvix in our
region,” said Ivan Srejber, Group Executive Chairman, Endotherapeutics Australia
and New Zealand.

*Photocure is the exclusive distributor for the HIVECT system in the Nordic
countries

For further information, please contact:

Dan Schneider
President and CEO
Photocure ASA
Email: [email protected]

Erik Dahl
CFO
Photocure ASA
Tel: +47 45055000
Email: [email protected]

David Moskowitz
Vice President, Investor Relations
Photocure ASA
Tel: +1 202 280 0888
Email: [email protected]

Media and IR enquiries:
Geir Bjørlo
Corporate Communications (Norway)
Tel: +47 91540000
Email: [email protected]

Note to editors:
All trademarks mentioned in this release are protected by law and are registered
trademarks of Photocure ASA.

This press release may contain product details and information which are not
valid, or a product is not accessible, in your country. Please be aware that
Photocure does not take any responsibility for accessing such information which
may not comply with any legal process, regulation, registration or usage in the
country of your origin.

About Endotherapeutics
Endotherapeutics was founded in 1999 by Ivan Srejber with a small team, with a
focus on innovative, specialised medical technologies that provided access to
life-improving solutions to healthcare professionals and their patients.

With its mission of “Improving Healthcare” and a strong focus on its values,
Endotherapeutics is proud of its strong reputation and relationships with
customers and partnering with leading international healthcare companies.

Over 20 years of experience has allowed Endotherapeutics to develop extensive
knowledge of the Australian and New Zealand healthcare systems. This includes
the registration and reimbursement of new medical technologies and their
successful sales and marketing.

Today Endotherapeutics is a leading Australian healthcare technologies company
that operates across both Australia and New Zealand. In New Zealand
Endotherapeutics is known and trades as Endoventure, and is a highly regarded
and customer focused organisation, whose Managing Director is Rachelle Hodgson.

Endotherapeutics contacts:
Ivan Srejber
Group Executive Chairman | Australia & New Zealand
Email: [email protected]

New Zealand contact information:
Rachelle Hodgson
Managing Director
Endoventure
Email: [email protected]

About Bladder Cancer
Bladder cancer ranks as the seventh most common cancer worldwide with 1 720 000
prevalent cases (5-year prevalence rate)[1a], 573 000 new cases and more than
200 000 deaths annually in 2020.[1b]

Approx. 75% of all bladder cancer cases occur in men.[1] It has a high
recurrence rate with an average of 61% in year one and 78% over five years.[2]
Bladder cancer has the highest lifetime treatment costs per patient of all
cancers.[3]

Bladder cancer is a costly, potentially progressive disease for which patients
have to undergo multiple cystoscopies due to the high risk of recurrence. There
is an urgent need to improve both the diagnosis and the management of bladder
cancer for the benefit of patients and healthcare systems alike.

Bladder cancer is classified into two types, non-muscle invasive bladder cancer
(NMIBC) and muscle-invasive bladder cancer (MIBC), depending on the depth of
invasion in the bladder wall. NMIBC remains in the inner layer of cells lining
the bladder. These cancers are the most common (75%) of all BC cases and include
the subtypes Ta, carcinoma in situ (CIS) and T1 lesions. In MIBC the cancer has
grown into deeper layers of the bladder wall. These cancers, including subtypes
T2, T3 and T4, are more likely to spread and are harder to treat.[4]
[1] Globocan. a) 5-year prevalence / b) incidence/mortality by population.
Available at: https://gco.iarc.fr/today, accessed [April 2021].
[2] Babjuk M, et al. Eur Urol. 2019; 76(5): 639-657

[3] Sievert KD et al. World J Urol 2009;27:295-300

[4] Bladder Cancer. American Cancer
Society. Bladder Cancer

About Hexvix[®]/Cysview[®] (hexaminolevulinate HCl)
Hexvix/Cysview is a drug that preferentially accumulates in cancer cells in the
bladder making them glow bright pink during Blue Light Cystoscopy (BLC[®]). BLC
with Hexvix/Cysview[ ]improves the detection of tumors and leads to more
complete resection, fewer residual tumors and better management decisions.

Cysview is the tradename in the U.S. and Canada, Hexvix is the tradename in all
other markets. Photocure is commercializing Cysview/Hexvix directly in the U.S.
and Europe, and has strategic partnerships for the commercialization of
Hexvix/Cysview in China, Canada, Chile, Australia and New Zealand. Please refer
to https://photocure.com/partnering-with-photocure/our-partners/ for further
information on our commercial partners.

About Photocure ASA
Photocure: The Bladder Cancer Company delivers transformative solutions to
improve the lives of bladder cancer patients. Our unique technology, making
cancer cells glow bright pink, has led to better health outcomes for patients
worldwide. Photocure is headquartered in Oslo, Norway and listed on the Oslo
Stock Exchange (OSE: PHO). For more information, please visit us at
www.photocure.com, www.hexvix.com, www.cysview.com

Kilde